当前位置：
X-MOL 学术
›
Oncoimmunology
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer
OncoImmunology ( IF 7.2 ) Pub Date : 2023-11-13 , DOI: 10.1080/2162402x.2023.2275846 Maximilian Marhold 1 , Simon Udovica 2 , Anna Halstead 3 , Mona Hirdler 4, 5 , Muna Ferner 2 , Kerstin Wimmer 6 , Zsuzsanna Bago-Horvath 5 , Ruth Exner 6 , Florian Fitzal 6 , Kathrin Strasser-Weippl 2 , Tim Robinson 3 , Rupert Bartsch 1
OncoImmunology ( IF 7.2 ) Pub Date : 2023-11-13 , DOI: 10.1080/2162402x.2023.2275846 Maximilian Marhold 1 , Simon Udovica 2 , Anna Halstead 3 , Mona Hirdler 4, 5 , Muna Ferner 2 , Kerstin Wimmer 6 , Zsuzsanna Bago-Horvath 5 , Ruth Exner 6 , Florian Fitzal 6 , Kathrin Strasser-Weippl 2 , Tim Robinson 3 , Rupert Bartsch 1
Affiliation
Based upon results of the KEYNOTE-522 trial and following approval by regulatory authorities, the addition of pembrolizumab to chemotherapy is now the standard-of-care for the treatment of early tr...
中文翻译：
免疫相关不良事件的出现与接受派姆单抗治疗早期三阴性乳腺癌的患者的病理完全缓解相关
根据 KEYNOTE-522 试验的结果并经监管机构批准，在化疗中添加派姆单抗现已成为治疗早期癌症的标准疗法。
更新日期：2023-11-15
中文翻译：
免疫相关不良事件的出现与接受派姆单抗治疗早期三阴性乳腺癌的患者的病理完全缓解相关
根据 KEYNOTE-522 试验的结果并经监管机构批准，在化疗中添加派姆单抗现已成为治疗早期癌症的标准疗法。
京公网安备 11010802027423号